The prevalence and factors associated with coronary heart disease in patients with gout

Background. Gout is associated with increased risk of cardiovascular disease (CVD) morbidity and mortality. Therefore, an association between coronary heart disease (CHD) and gout deserves careful examination.
The aim of this study was to determine the prevalence of CHD and factors associated with CHD in patients (pts) with gout.
Methods. 286 male patients with gout were included; age – 51.2 [42.8; 59.4] years (ys), disease duration – 6.2 [3.8; 12.1] ys. All patients underwent standard clinical examination, screening traditional risk factors (TRF) of CVD. We estimated the adjusted odds ratio (OR) and 95% confidence interval (95% CI).
Results. CHD was found in 111 out of the 286 pts (38.8%), MI had a history in 29.7%. Compared to individuals with CHD, participants without CHD were older (56.7 [52.1; 61.1] vs 46.2 [40.6; 53.4] ys), had longer duration of gout (9.3 [4.7; 15.1] vs 5.6 [3.3; 9.7] ys) (for all p<0.05). Abdominal obesity (OR=3.6; 95% CI: 1.2–10.9), family history of CHD (OR=2.2; 95% CI: 1.3–5.4), disease duration of gout more 10 ys (OR=2.8; 95% CI: 1.6–4.7), age of gout onset <35 ys (OR=5.5; 95% CI: 2.6–11.7), intraosseous tophi (OR=3.03; 95% CI: 1.8–5.01), nephrolithiasis (OR=1.7; 95% CI: 1.04–3.04), renal failure (OR=5.6; 95% CI: 2.7–11.4), serum total cholesterol (TC) (OR=1.6; 95% CI: 1.0–2.8), serum creatinine (OR=2.5; 95% CI: 1.2–5.1), increased the risk for CHD in patients with a gout.
Conclusions. The prevalence of CHD was 38.8% among individuals with gout (third of patients had a history of MI 29.7%). Our study showed that both TRFs of CVD and the severity of gout and a history of renal failure contribute to the development of CHD in patients with gout.

1. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380-390. doi: 10.1038/s41584-020-0441-1

2. Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: Case-control study. Ann Rheum Dis. 2016; 75(1): 210-217. doi: 10.1136/annrheumdis-2014-206410

3. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: An update on prevalence and treatment options. BMC Med. 2017;15(1):123. doi: 10.1186/s12916-017-0890-9

4. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894-900. doi: 10.1161/CIRCULATIONAHA.107.703389

5. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum. 2006;54(8):2688-2696. doi: 10.1002/art.22014

6. De Vera MA, Rahman MM, Bhole V, Kopec JA, Choi HK. Independent impact of gout on the risk of acute myocardial infarction among elderly women: A population-based study. Ann Rheum Dis. 2010;69(6):1162-1164. doi: 10.1136/ard.2009.122770

7. Sanchez-Lozada LG, Rodriguez-Iturbe B, Kelley EE, Nakagawa T, Madero M, Feig DI, et al. Uric acid and hypertension: An update with recommendations. Am J Hypertens. 2020;33(7):583-594. doi: 10.1093/ajh/hpaa044

8. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282(6):F991-F997. doi: 10.1152/ajprenal.00283.2001

9. Park JJ, Roudier MP, Soman D, Mokadam NA, Simkin PA. Prevalence of birefringent crystals in cardiac and prostatic tissues, an observational study. BMJ Open. 2014;4(7):e005308. doi: 10.1136/bmjopen-2014-005308

10. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707

11. Russian Society of Cardiology. 2020 clinical practice guidelines for stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076 (In Russ.). doi: 10.15829/1560-4071-2020-4076

12. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Russian Journal of Cardiology. 2022;27(7):5155 (In Russ.). doi: 10.15829/1560-4071-2022-5155

13. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339

14. Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-779. doi: 10.1136/annrheumdis-2021-221733

15. Liu SC, Xia L, Zhang J, Lu XH, Hu DK, Zhang HT, et al. Gout and risk of myocardial infarction: A systematic review and metaanalysis of cohort studies. PLoS One. 2015;10(7):e0134088. doi: 10.1371/journal.pone.0134088

16. Huang KH, Tai CJ, Tsai YF, Kuan YH, Lee CY. Correlation between gout and coronary heart disease in Taiwan: A nationwide population-based cohort study. Acta Cardiol Sin. 2019;35(6):634-640. doi: 10.6515/ACS.201911_35(6).20190403B

17. Liang L, Hou X, Bainey KR, Zhang Y, Tymchak W, Qi Z, et al. The association between hyperuricemia and coronary artery calcification development: A systematic review and meta-analysis. Clin Cardiol. 2019;42(11):1079-1086. doi: 10.1002/clc.23266

18. Wijnands JM, Boonen A, Dagnelie PC, van Greevenbroek MM, van der Kallen CJ, Ferreira I, et al. The cross-sectional association between uric acid and atherosclerosis and the role of low-grade inflammation: the CODAM study. Rheumatology (Oxford). 2014;53(11):2053-2062. doi: 10.1093/rheumatology/keu239

19. Essex MN, Hopps M, Bienen EJ, Udall M, Mardekian J, Makinson GT. Evaluation of the relationship between serum uric acid levels and cardiovascular events in patients with gout: A retrospective analysis using electronic medical record data. J Clin Rheumatol. 2017;23(3):160-166. doi: 10.1097/RHU.0000000000000496

20. Wu J, Lei G, Wang X, Tang Y, Cheng H, Jian G, et al. Asymptomatic hyperuricemia and coronary artery disease in elderly patients without comorbidities. Oncotarget. 2017;8(46):80688-80699. doi: 10.18632/oncotarget.21079

21. Busso N, So A. Mechanisms of inflammation in gout. Arthritis Res Ther. 2010;12(2):206. doi: 10.1186/ar2952

22. Schjerning A-M, McGettigan P, Gislason G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol. 2020;17(9):574-584. doi: 10.1038/s41569-020-0366-z

23. Yang Y, Xian W, Wu D, Huo Z, Hong S, Li Y, et al. The role of obesity, type 2 diabetes, and metabolic factors in gout: A Mendelian randomization study. Front Endocrinol (Lausanne). 2022;13:917056. doi: 10.3389/fendo.2022.917056

24. Barskova VG, Ilinykh EV, Eliseev MS, Zilov AV, Nasonov EL. Cardiovascular risk in patients with gout. Obesity and Metabolism. 2006;3(3):40-44 (In Russ.).

25. Markelova EI, Eliseev MS, Popkova TV, Ilinyh EV, Glukhova SI, Barskova VG. Prevalence and risk factors influencing the development of arterial hypertension in patients with a gout. NauchnoPrakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(6):701-707 (In Russ.). doi: 10.47360/1995-4484-2020-701-707

26. Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: Meta-analysis of observational studies. Arthritis Res Ther. 2015;17(1):90. doi: 10.1186/s13075-015-0610-9

27. Yu KH, Kuo CF, Luo SF, See LC, Chou IJ, Chang HC, et al. Risk of end-stage renal disease associated with gout: A nationwide population study. Arthritis Res Ther. 2012;14(2):R83. doi: 10.1186/ar3806